<DOC>
	<DOCNO>NCT00181584</DOCNO>
	<brief_summary>The primary objective study determine whether zoledronic acid ( Zometa ) give annually increase bone mineral density men receive hormone therapy prostate cancer .</brief_summary>
	<brief_title>Zoledronic Acid Prevent Bone Loss During Androgen Deprivation Therapy Prostate Cancer</brief_title>
	<detailed_description>- Patients randomize 2 group . At screen visit , bone mineral density test perform determine patient osteoporosis . Patients osteoporosis treat Zometa . Patients without osteoporosis randomly assign receive either Zometa placebo . - Zometa administer intravenously 15 minute prior one year study . - All patient ask take over-the-counter oral calcium ( 500mg daily ) daily multi-vitamin ( contain 400-500 I.U vitamin D ) study . - All patient clinic visit every 3 month blood test report side effect may experience . At month 12 , bone mineral density test repeat .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Adenocarcinoma prostate Current androgen deprivation therapy expect duration treatment great equal 12 month Corrected serum calcium &gt; 8.4mg/dl &lt; 10.6mg/dl Serum creatinine &lt; 2.0mg/dl History bone metastases bone scan Treatment bisphosphonate within one year History metabolic disease Chronic use glucocorticoid , anticonvulsant , suppressive dos thyroxine within one year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Androgen deprivation therapy</keyword>
	<keyword>bone loss</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>Zoledronic Acid</keyword>
	<keyword>Zometa</keyword>
</DOC>